Decreased exposure to sunitinib due to concomitant administration of ifosfamide: Results of a phase i and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

British Journal of Cancer

Volumn 102, Issue 12, 2010, Pages 1699-1706

  Hamberg, P ^a   Steeghs, N ^b   Loos, W J ^a   Van De Biessen, D ^a   Den Hollander, M ^b   Tascilar, M ^a   Verweij, J ^a   Gelderblom, H ^b   Sleijfer, S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug interaction; Ifosfamide; Pharmacokinetic; Phase I; Sunitinib; VEGF

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG METABOLITE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL COUNT; CHEMOTHERAPY INDUCED EMESIS; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ENDOTHELIUM CELL; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEARTBURN; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; UVEA MELANOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; IFOSFAMIDE; INDOLES; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PYRROLES;

EID: 77953291227     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605696     Document Type: Article

References (33)

1. Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q (2004) Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatography with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 1024: 87-94
2. Bello C, Houk B, Sherman L, Misbah S, Sarapa N, Smeraglia J, Haung X (2005) Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J Clin Oncol 23: 3078
3. Boddy AV, Cole M, Pearson AD, Idle JR (1995) The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 36: 53-60
4. Boucher Y, Jain RK (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52: 5110-5114
5. Boven E, Massard C, Armand JP, Tiller C, Hartog V, Brega NM, Contouriotis AM, Law CNJ, Soria J (2008) Phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumors. Ann Oncol 19: viii156
6. Cardoso F, Canon JL, Amadori D, Dirix L, Villa E, Aldrighetti D, Machiels JP, Verkh L, Kern K, Giorgetti C (2009) Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer. Eur J Cancer Suppl 7: 283 5075
7. De Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ (2010) Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 51: 934-941
8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338
9. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32
10. Dias S, Shmelkov SV, Lam G, Rafii S (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99: 2532-2540
11. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35
12. Friedman HS, Vredenburgh JJ, Desjarddins A, Janney DE, Peters KB, Friedman AH, Gururangan S, Reardon A (2009) A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent glioma. J Clin Oncol 27: e13024
13. Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim S, Chao R, Wilding G (2009) Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors; updated phase I study results. J Clin Oncol 27: e14509
14. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813
15. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study (2007) Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25: 3144-3150 (Pubitemid 47218064)
16. Mariani G, Cardoso F, Besse-Hammer T, Vigano L, Liljegren A, Verkh L, Huang X, Giorgetii C, Bergh J, Gianni L (2008) Sequential administration of sunitinib and docetaxel in women with advanced breast cancer: an exploratory evaluation. J Clin Oncol 26: 18s
17. Michaelson MD, Schwarzberg A, Ryan DP, McDermott D, Shapiro GI, Tye L, Chen I, Selaru P, Wang E, Zhu A (2008) A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors. Ann Oncol 19: viii156
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
19. Reck M, Frickhofen N, Gatzemeier U, Fuhr H, Lanzalon S, Lechuga J, Wang E, Chao R, Felip E (2007) A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25: 18s
20. Robert F, Sandler A, Schiller JH, Ilagan J, Vermeulen W, Harper K, Liu G, Tye L, Chao R, Traynor A (2007) A phase I dose-escalation and pharmacokinetic study of sunitinib plus docetaxel in patients with advanced solid tumors. J Clin Oncol 25: 18s
21. Riedel F, Götte K, Goessler U, Sadick H, Hörmann K (2004) Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res 24: 2179-2183
22. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71: 105-113
23. Royce M, Chiorean EG, Sweeney C, Verschraegen C, Lee FC, Jones S, Rabinowitz I, Bello A, Chao R, Burris H (2008) A phase I dose-finding study of sunitinib in combination with capecitabine in patients with advanced solid tumors. Breast Cancer Symposium Proceedings. 169
24. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273
25. Simakajornboon N, Szerlip NJ, Gozal E, Anonetapipat JW, Gozal D (2001) In vivo PDGF beta receptor activation in the dorsocaudal brainstem of the rat prevents hypoxia-induced apoptosis via activation of Akt and BAD. Brain Res 895: 111-118
26. Starling N, Vázquez F, Cunningham D, Chau I, Ramos FJ, Saunders MP, Iveson TJ, Verkh L, Tursi J, Carrato A (2008) Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-näive metastatic colorectal cancer (mCRC). J Clin Oncol 26: 18s
27. Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S (2008) Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98: 1731-1735
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
29. Tran J, Master Z, Yu JL, Rak JL, Dumont DJ, Kerbel RS (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-4354
30. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134
31. Washington C, Eli M, Bello C, Schaaf L, Polasek E, Tan LH, Scigalla P, Sarapa N (2003) The effect of ketoconazole, a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics in Caucasian and Asian Healthy subjects. J Clin Oncol 22: 553
32. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147
33. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, Wilding G, Logothetis CJ, Chen I, Chow Maneval E, George D (2009) Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 27: 15s